Purpose of review Systemic lupus erythematosus (SLE) is caused by a combination of genetic and acquired immunodeficiencies and environmental factors including infections. An association with Epstein-Barr virus (EBV) has been established by numerous studies over the past decades. Here, we review recent experimental studies on EBV, and present our integrated theory of SLE development.
INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with female predominance [1] . Symptoms include rash, oral ulcers, arthritis, serositis, renal complications, and hematologic and immunological disorders including production of autoantibodies against nuclear components (anti-double-stranded DNA, anti-Sm, antihistone, and antiribonucleoprotein) ( Table 1 ) [1] [2] [3] [4] .
The disease is characterized by periods of disease flares alternating with treatment-induced remissions. Known predisposing congenital and/or acquired immunodeficiencies include complement deficiencies (especially, C1q and C4), impaired cytokine regulation, T-cell proliferation, and B-cell functions including altered immunoglobulin production (Table 1) [1, 4, 5] . Together with external factors, predominantly infections, development of SLE is elicited. Epstein-Barr virus (EBV) latently infects the majority of the world's population [6] (Fig. 1 , Table 2 ) [7] [8] [9] . Primary infection commonly takes place during childhood, causing a mild or asymptomatic infection. However, 30-70% of individuals acquiring a primary EBV infection during adolescence develop infectious mononucleosis [10] with symptoms resembling those of SLE [11] [12] [13] . Following primary infection, EBV persists in a latent form in memory B-cell, evading the host's immune system and preventing apoptosis of the infected cells [8] . Occasionally, EBV reactivates leading to expression of lytic genes and replication of the viral genome resulting in production and release of new infectious virus, which can infect epithelial, B, T, and natural killer cells (reviewed in [8, 9] ). Also in the lytic cycle, EBV has effective immune evasion strategies including expression of proteins with antiapoptotic and immunomodulating functions (reviewed in [9] ).
Various mechanisms have been proposed for activation of autoreactive lymphocytes caused by infections, including molecular mimicry, bystander activation, and superantigen activation (reviewed in [14] ). However, none of these fully explains all aspects of SLE cause.
Epstein-Barr virus in systemic lupus erythematosus
EBV has for decades been suspected to be an environmental agent in the development of SLE and an association by now is widely accepted. An altered infection pattern with poor control of the latent EBV infection and exacerbations of an active lytic cycle has been established. Previous findings comprise high viral loads, increased EBV mRNA expression, and elevated humoral responses against EBV (reviewed in [11, 15, 16] ). Already in 1971, an association was demonstrated by increased EBV antibody titers in SLE patients [15, 17] . Numerous studies confirmed higher frequencies and elevated titers of EBV-directed antibodies, against lytic cycle antigens, in SLE patients compared with healthy controls, indicating frequent EBV reactivation (reviewed in [11, 18] confirmed these findings in renal tissue from 51 young (6-16 years) SLE patients with lupus nephritis, and furthermore showed a positive correlation between LMP1 and the classification of lupus nephritis suggesting that renal EBV infection may be directly involved in the development of lupus nephritis.
The latent state EBV-antigen LMP2A (that serves as a survival signal that normally is generated by antigen binding to the B-cell receptor) was recently demonstrated to be an important mediator of SLE in a mouse model [24 && ]. To mimic LMP2A expression in EBV-infected human B-cell, they used a system with conditional expression of LMP2A in B-cell. This resulted in B-cell hyperactivity and differentiation into plasma cells producing low-affinity antibodies and, most interestingly, it led to SLE-like features including production of anti-dsDNA, anticardiolipin, and immune complex deposition in the kid-
Previous studies have demonstrated that SLE patients have impaired EBV-specific T-cell responses (reviewed in [9] ). We have recently further evaluated these responses by ex-vivo stimulation of whole blood samples from 28 SLE patients compared with 28 sex and age-matched healthy controls. Results showed significantly fewer CD8 þ and CD4 þ T-cells responding to EBNA1 and early antigen diffuse by quantification of the surface activation marker CD69 and the production of IFN-g by flow cytometry [25 && ]. Interestingly, an inverse association between EBV-specific T-cells and production of EBV-directed antibodies was observed, and disease activity was inversely correlated with the number of early antigen diffuse-specific T-cells. As cell-mediated immunity is crucial to control latent EBV infection, these results suggest impaired control of EBV in SLE patients with a shift toward more frequent reactivation and a humoral immune response attempting to control EBV activity. This impaired EBV control seems to contribute to the exacerbation of SLE disease symptoms [ autoimmune hepatitis) developed chronic active EBV infection with EBV-encoded RNA-positive lymphocytes found in both liver and gastric mucosal biopsies and in high concentrations in the CD4 þ T-cells in the blood [27] . Similarly, an 86-year-old woman with SLE developed a rare form of EBV-positive plasmablastic lymphoma in the colon [28] . Additionally, two case reports described how EBV-positive lymphoproliferative disorders can be initially misdiagnosed as a type of lupus since symptoms overlap and can include the presence of antinuclear antibodies [29, 30] .
Other viruses in systemic lupus erythematosus
Other infectious agents especially other human herpes viruses (HHVs) have been associated with SLE including cytomegalovirus (CMV) and Varicella zoster virus (VZV [33, 34] have also been associated with SLE [14, 15, 35] , presumably as a result of general immunodeficiencies.
Epstein-Barr virus in other autoimmune diseases
EBV has been associated with other autoimmune diseases including Sjögren's syndrome, rheumatoid arthritis (RA), and multiple sclerosis (MS), all of which (like SLE) are believed to be multifactorial with a genetic susceptibility combined with environmental triggers, and are characterized by partly overlapping symptoms and autoantibodies.
Sjögren's syndrome can present both as a primary and secondary disease (often associated with SLE or RA) and is mainly characterized by disorders of the exocrine glands [36] . RA is the most common of these diseases and symptoms especially comprise arthritis [37] . MS is an autoimmune disorder in the central nervous system (CNS) with chronic inflammatory demyelinating conditions [38] .
Two recent studies have extended the knowledge on the association between EBV infection and Sjögren's syndrome. Croia et al. Interestingly, Westergaard et al. found that the immune response to the latent stage EBNA1 was altered in RA patients with highly increased titers ]. In addition, Cornillet et al. [41] demonstrated an association between antibodies to a citrullinated EBNA1 peptide and antibodies against other characteristically citrullinated peptides in RA patients. The altered immune response to EBV in RA patients was also demonstrated by Erre et al., by showing increased EBV DNA positivity in PBMCs in 79.2% of RA patients compared with 56.9% of healthy controls. Furthermore, they found an increased prevalence in RA patients of both EBNA1 IgG (90% compared with 69% of healthy controls) and EBV-early antigen IgG (37% compared with 10.3% of healthy controls) [42] .
The role of EBV in MS development has been investigated for a long time. A characteristic (although not specific) feature of MS is the intrathecal production of antibodies (oligoclonal bands) [38] .
This presumably reflects the presence of EBV-infected B-cell in the CNS, in line with a theory of entry of EBV-specific T-cells into CNS causing MS relapses (reviewed in [43] ). Actually, van Nierop et al. [44 & ] recently demonstrated increased frequencies of intrathecal T-cell reactivity in MS patients using peripheral autologous EBV-infected B-cell as antigenpresenting cells. An uncontrolled latent EBV infection was also established by Nejati et al. [45 ] with a significantly higher EBV DNA load in PBMCs from MS patients compared with healthy controls, which was inversely associated with vitamin D concentrations, suggesting a vitamin D contribution to the immune modulation of EBV in MS patients. The altered immune reaction to EBV in MS patients also entails elevated EBV antibody titers [ Discussion: the role of Epstein-Barr virus and other viruses in the etiology of systemic lupus erythematosus and other autoimmune diseases EBV is an important, extremely successful HHV, which infects essentially all of mankind (Fig. 1,  Table 2 ). However, this fact is also a common objection to EBV having a causative role in SLE and other autoimmune diseases. A related question is how EBV can cause several seemingly different autoimmune diseases. These questions can simply be answered by the role of individual genetically determined immunoprofiles and by individual combinations of infections, other environmentally induced immunomodulations (including ultraviolet light, radiation, and chemicals), viral reactivations, and treatment regimes (Fig. 2) .
EBV infects epithelial cells and other cell types and it affects the immune system of the host directly by infection of lymphocytes with subsequent immortalization and indirectly by expression of immunomodulating viral antigens. EBV infection may develop diverse autoreactivities in different individuals according to genetic susceptibility and immune condition (Table 1) , the types of infected cells, the sites of reactivation, and immune responses against EBV and in this way be a contributing agent to diverse yet overlapping autoimmune diseases.
An apparent paradox is how current treatment, based on immunosuppression, can be successful against a virus-induced autoimmune disease like SLE. This paradox may be resolved by the biology of EBV, its tropism for B-cell and the ability of immunosuppression to limit the spreading of EBV and infected B-cell in addition to its dampening of inflammation. This is supported by the ability of anti-CD20 drugs to reduce disease activity [50] .
CONCLUSION
In our opinion, the evidence for a causative role of EBV in SLE and other autoimmune diseases is so compelling that future research should be focused on the additional role(s) of other (herpes)viruses and possible new therapies based on immunomodulation and/or antiviral drugs. Currently, there is a scarcity of vaccines and drugs with efficacy against EBV. The work explores the T-cell responses against two EBV antigens, EBNA1 and early antigen diffuse, and demonstrates a significantly reduced fraction of functioning EBV-specific T-cells in SLE patients compared with healthy controls. Interestingly, these results were accompanied by higher titers of EBV-directed antibodies and were inversely correlated with disease activity of SLE patients.
